Primary CNS Lymphoma in an Immunocompetent Patient: An Unusual Case Illustrating the Usual Problems Facing Brain Tumour Management in a Lower-Middle-Income Country
DOI:
https://doi.org/10.36552/pjns.v26i4.680Keywords:
Primary CNS Lymphoma, Immunocompetent, Multidisciplinary cancer careAbstract
Primary central nervous system lymphoma (PCNSL) is a rare extra-nodal non-Hodgkin lymphoma (NHL). It primarily affects the immunocompromised but is rarely seen in immunocompetent individuals. The pitfalls in the healthcare system of lower-middle-income countries produce many obstacles, impeding timely diagnosis, timely treatment, and optimal quality of care. A 57-year-old immunocompetent, diabetic female presented with progressive generalised fatiguability, forgetfulness, and subtle behavioural changes for the last one and a half years. MRI revealed an area of gyri from dense post-contrast enhancement in the right posterior parietal region. Her symptoms kept aggravating with periods of partial remission as steroids were being administered. Reasons for delays in diagnosis and hence timely treatment include lack of primary care referral, conflicting neurosurgical opinion, and absence of multidisciplinary team management. A right posterior parietal parasagittal craniotomy was performed to excise the lesion. The patient was subsequently referred for adjuvant therapy. We use our patient's clinical journey to exemplify the structural barriers to providing optimal and timely care for brain tumour patients in a developing country. Primary CNS Lymphomas in immunocompetent patients are rare. Poor infrastructure and referral pathways contribute to delayed diagnosis. Lack of multi-disciplinary care owing to organisational issues is a major problem faced by brain tumour patients in a lower-middle-income country like ours. Brain tumour management requires a specialist multidisciplinary team approach to ensure timely diagnosis and optimal treatment
References
Schaff LR, Grommes C. Updates on primary central nervous system lymphoma. Current oncology reports. 2018;20(2):1-10.
Chukwueke UN, Nayak L. Central Nervous System Lymphoma. Hematol Oncol Clin North Am. 2019;33(4):597-611.
Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood reviews. 2008;22(5):261-281.
Makino K, Nakamura H, Kino T, Takeshima H, Kuratsu J-i. Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. Surgical neurology. 2006;66(5):503-506.
Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non?Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer. 2002;95(7):1504-1510.
Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol. 1999;43(3):219-226.
Izquierdo C, Velasco R, Vidal N, et al. Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. Neuro Oncol. 2016;18(5):707-715.
Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35(21):2410-2418.
Macfarlane S, Racelis M, Muli-Musiime F. Public health in developing countries. Lancet. 2000;356(9232):841-846.
Abbasi AN. Cancer management is a multidisciplinary team work. J Coll Physicians Surg Pak. 2011;21(5):259-261
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Mohammad Ashraf, Minaam Farooq, Muhammad Ahmad Malik, Shazib Ali, Shehreen Sohail, Syed Shahzad Hussain, Naveed AshrafThe work published by PJNS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Copyrights on any open access article published by Pakistan Journal of Neurological Surgery are retained by the author(s).